Literature DB >> 24369119

Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function.

Piero Pingitore1, Carlo Pirazzi2, Rosellina M Mancina3, Benedetta M Motta4, Cesare Indiveri5, Arturo Pujia6, Tiziana Montalcini6, Kristina Hedfalk7, Stefano Romeo8.   

Abstract

The patatin-like phospholipase domain containing 3 (PNPLA3, also called adiponutrin, ADPN) is a membrane-bound protein highly expressed in the liver. The genetic variant I148M (rs738409) was found to be associated with progression of chronic liver disease. We aimed to establish a protein purification protocol in a yeast system (Pichia pastoris) and to examine the human PNPLA3 enzymatic activity, substrate specificity and the I148M mutation effect. hPNPLA3 148I wild type and 148M mutant cDNA were cloned into P. pastoris expression vectors. Yeast cells were grown in 3L fermentors. PNPLA3 protein was purified from membrane fractions by Ni-affinity chromatography. Enzymatic activity was assessed using radiolabeled substrates. Both 148I wild type and 148M mutant proteins are localized to the membrane. The wild type protein shows a predominant lipase activity with mild lysophosphatidic acid acyl transferase activity (LPAAT) and the I148M mutation results in a loss of function of both these activities. Our data show that PNPLA3 has a predominant lipase activity and I148M mutation results in a loss of function.
Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adiponutrin (ADPN); Lysophosphatidic acid acyltransferase activity; Patatin-like phospholipase domain containing 3 (PNPLA3); Pichia pastoris; Triglyceride hydrolase activity; rs738409 (I148M)

Mesh:

Substances:

Year:  2013        PMID: 24369119     DOI: 10.1016/j.bbalip.2013.12.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  63 in total

Review 1.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 2.  Structure, Function and Metabolism of Hepatic and Adipose Tissue Lipid Droplets: Implications in Alcoholic Liver Disease.

Authors:  Sathish Kumar Natarajan; Karuna Rasineni; Murali Ganesan; Dan Feng; Benita L McVicker; Mark A McNiven; Natalia A Osna; Justin L Mott; Carol A Casey; Kusum K Kharbanda
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

Review 3.  Genetics and epigenetic factors of Wilson disease.

Authors:  Valentina Medici; Janine M LaSalle
Journal:  Ann Transl Med       Date:  2019-04

Review 4.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

5.  Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma.

Authors:  Maneerat Raksayot; Natthaya Chuaypen; Apichaya Khlaiphuengsin; Nutcha Pinjaroen; Sombat Treeprasertsuk; Yong Poovorawan; Yasuhito Tanaka; Pisit Tangkijvanich
Journal:  J Gastroenterol       Date:  2018-11-30       Impact factor: 7.527

Review 6.  Wilson disease.

Authors:  Anna Członkowska; Tomasz Litwin; Petr Dusek; Peter Ferenci; Svetlana Lutsenko; Valentina Medici; Janusz K Rybakowski; Karl Heinz Weiss; Michael L Schilsky
Journal:  Nat Rev Dis Primers       Date:  2018-09-06       Impact factor: 52.329

Review 7.  PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.

Authors:  Li-Zhen Chen; Yong-Ning Xin; Ning Geng; Man Jiang; Ding-Ding Zhang; Shi-Ying Xuan
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

8.  The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro.

Authors:  S Pillai; S Duvvuru; P Bhatnagar; W Foster; M Farmen; S Shankar; C Harris; E Bastyr; B Hoogwerf; A Haupt
Journal:  Pharmacogenomics J       Date:  2017-11-21       Impact factor: 3.550

Review 9.  New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease.

Authors:  Mary Barbara; Andrea Scott; Naim Alkhouri
Journal:  Hepatobiliary Surg Nutr       Date:  2018-10       Impact factor: 7.293

Review 10.  PNPLA3 genetic variation in alcoholic steatosis and liver disease progression.

Authors:  Felix Stickel; Jochen Hampe; Eric Trépo; Christian Datz; Stefano Romeo
Journal:  Hepatobiliary Surg Nutr       Date:  2015-06       Impact factor: 7.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.